Calidi Biotherapeutics, Inc. (CLDWW)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Allan J. Camaisa | CEO & Chairman of the Board | 504.78k | -- | 1961 |
| Mr. Andrew C. Jackson | Chief Financial Officer | 474.07k | -- | 1969 |
| Ms. Wendy Pizarro Campbell Esq. | Chief Legal, Chief Corporate Dev, Chief Diversity & Corp Sec. | 469.64k | -- | 1972 |
| Dr. Boris Minev M.D., Ph.D. | President of Medical & Scientific Affairs | 413.28k | -- | 1964 |
| Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D. | Head of Technical Operations & Chief Scientific Officer | -- | -- | 1980 |
| Mr. Guy Travis Clifton M.D. | Chief Medical Officer | -- | -- | -- |
Calidi Biotherapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 28
Description
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available